- SURMOUNT-2: Tirzepatide Rings Up Major Weight Loss in T2D Medscape
- Lilly’s SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes | Eli Lilly and Company Investors | Eli Lilly and Company
- ADA 2023 – Toxicity undermines Boehringer and Zealand’s incretin evaluate.com
- Step aside Ozempic and Wegovy — ‘landmark’ trial results for weight-loss drug Mounjaro just dropped, and they Business Insider India
- Lilly’s phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight | Eli Lilly and Investors | Eli Lilly and Company
- View Full Coverage on Google News
Read original article here